The purpose of this study is:
To evaluate the efficacy of the drugs under study for treating chronic plaque psoriasis.
50 patients will be selected from both sexes, healthy, between 18 and 65 years with a
clinical diagnosis of chronic plaque psoriasis with PASI <20%, according to the criteria of
inclusion and exclusion.
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Inclusion Criteria:
- Age range: Between 18 and 65
- A patient with chronic plaque psoriasis
- PASI <20%
- Presence of bilateral lesions with at least 2 cm in diameter and each with some
degree of symmetry
- Levels of serum calcium and phosphorus within the normal range of reference or in
case of changes, classified as irrelevant by the investigator
- In the case of female patients, agreement or maintenance of safe use of contraception
such as barrier (condom, diaphragm), hormonal contraceptives (pills, implants or
injections), IUDs, or abstinence (no sex)
- Reading, understanding, agreement and signature of the patient in the Term of
Consent.
Exclusion Criteria:
- Gestation (confirmed by urine test indicator)
- Lactation
- History of hypersensitivity to components of medicines
- Psoriasis with different clinical presentation of the plates
- Clinical picture of psoriasis involving only the scalp, face, groin, armpit and / or
other intertriginous area
- Patient requires the use of concomitant medication (topical or systemic) that may
alter the course of the disease during the study period
- Use of any systemic treatment for psoriasis within 12 weeks before the start of the
study
- Use of systemic corticosteroids within 28 days before the start of the study
- Use of topical corticosteroids or other topical therapies in the areas of assessment
within 02 weeks before the start of the study
- Use of phototherapy (UVB / UVA-P) within 04 weeks before the start of the study
- Patients who have participated in another clinical study within 30 days before the
start of the study
- Use of any medication or possession of any disease which, in the opinion of the
investigator might interfere with the performance or interpretation of the study
- Laboratory tests changed (serum AST and ALT, alkaline phosphatase, urea and
creatinine, total bilirubin and fractions)
- Patients with demonstrated hypercalcemia or evidence of toxicity of vitamin D
- Other conditions deemed reasonable by the medical investigator as to the
disqualification of the individual from study participation